PepsiCo stock climbs as investors crowd into defensive staples during Wall Street slide
14 January 2026
1 min read

PepsiCo stock climbs as investors crowd into defensive staples during Wall Street slide

New York, January 14, 2026, 14:32 (EST) — Regular session

Shares of PepsiCo (PEP) climbed 1.7%, reaching $145.98 in afternoon trading on Wednesday.

The rise followed a shift toward defensive sectors after mixed earnings from major banks weighed on financial stocks, with losses spilling over into tech, Reuters reported. “These stocks had a strong run-up … so a pullback is not unusual,” said Jake Johnston, deputy CIO at Advisors Asset Management. 1

The Consumer Staples Select Sector SPDR Fund climbed 1.4%, even as the S&P 500 ETF dropped 0.8%. Coca-Cola, PepsiCo’s main U.S. soft-drink competitor, edged up slightly.

Evercore ISI stuck with its “In Line” rating on PepsiCo Wednesday, maintaining a $152 price target, according to a note reported by Investing.com. The “In Line” designation signals a hold recommendation. The broker pointed to upcoming management commentary in the quarterly results as the next key focus. 2

PepsiCo added 1.5% on Tuesday, January 13, finishing at $143.48 and marking its fourth straight day of gains, according to MarketWatch data. Still, the stock remains roughly 10% shy of its 52-week peak of $160.15 hit back in March. 3

The stock has been caught up in a broader debate over pricing, growth, and costs since the company laid out its “priorities to enhance shareholder value” last December, following talks with activist investor Elliott Investment Management. CEO Ramon Laguarta said the goal is to boost growth and margins “starting in 2026,” while Elliott partner Marc Steinberg called the discussions with management “collaborative.” 4

The downside is clear-cut: defensive bids often vanish fast when risk appetite picks up. A drop in demand, ramped-up promotions, or a tougher pricing battle in snacks and beverages could easily flip a “safe” trade into dead money.

Investors are keeping an eye on the broader market for signs on the duration of the rotation into staples, as rates and macro data continue to drive sector movements. Any abrupt change in rate expectations usually hits dividend-heavy consumer stocks quickly.

PepsiCo plans to release its fourth-quarter and full-year 2025 results on Feb. 3, with a press release and 10-K filing expected around 6:00 a.m. EST. The company will then hold a live Q&A session at 8:15 a.m. It’s also set to present at the Consumer Analyst Group of New York conference on Feb. 18, according to an SEC filing. 5

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Coney Island finally gets its own BID — and a July 2026 launch is now on the clock
Previous Story

Coney Island finally gets its own BID — and a July 2026 launch is now on the clock

Concentrix stock jumps as CNXC sets 2026 cash-flow target after $1.5 billion goodwill write-down
Next Story

Concentrix stock jumps as CNXC sets 2026 cash-flow target after $1.5 billion goodwill write-down

Go toTop